Neuroprotection in parkinson's disease: Analysis though group of expert's methodology;Neuroprotección en la enfermedad de parkinson: Análisis a través de la metodología de informadores clave

Neurologia

Volumn 24, Issue 2, 2009, Pages 113-124

  Linazasoro, G ^a,ad   Sesar, A ^b   Valldeoriola, F ^c   Compta, Y ^c   Herrero, M T ^d   Castrillo, J C Martínez ^e   Lozano, J J López ^f   Bergaretxe, A ^g   Vela, L ^h   Fernandez J M ⁱ   Castro, A ^b   Kulisevski, J ^j   Lezeano, E ^k   Vaamonde, J ^l   Del Val, J López ^m   Chacon, J ⁿ   Vivaneos, F ^o   Luquin, R ^p   Aguilar, M ^q   Burguera, J A ^r   Salvador, C ^s   Guisasola, L Menéndez ^s   Catalan, M J ^t   Mir, P ^u   Campos, V ^v   Grandas, F ^w   Minguez A ^x   Balaguer, E ^y   Yanez R ^z   Leiva, C ^aa   Ruiz, P García ^ab   Cubo, E ^ac   more..

^a Policliniea Gipuzkoa   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d UNIVERSITY OF MURCIA   (Spain)

^e HOSPITAL RAMÓN Y CAJAL   (Spain)

^f HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^g Hospital del Bidasoa   (Spain)

^h Fundaeion Hospital de Aleoreón   (Spain)

ⁱ HOSPITAL DE BASURTO   (Spain)

^j Hospital de la Santa Creu i San Pau   (Spain)

^k HOSPITAL DE CRUCES   (Spain)

^l Hospital Virgen de Alareos   (Spain)

^m Hospital Clinieo Universitario Lozano Blesa   (Spain)

ⁿ HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^o HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^p UNIVERSITY CLINIC OF NAVARRA   (Spain)

^q HOSPITAL MÚTUA DE TERRASSA   (Spain)

^r HOSPITAL UNIVERSITARIO LA FE   (Spain)

^s HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^t HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^u Hospital Virgen del Roeio   (Spain)

^v Centro Neuroelínie   (Spain)

^w HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^x HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^y HÔPITAL DU BOCAGE   (France)

^z HOSPITAL XERAL CALDE   (Spain)

^aa Hospital Clinieo

^ab Jimenez Diaz Foundation   (Spain)

^ac HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^ad Centro de Investigaeión Parkinson   (Spain)

more..

Author keywords

Animal models; Biomarkers; Neuroprotection; Parkinson's disease

Indexed keywords

ALPHA TOCOPHEROL; CEP 1347; CREATINE; DOPAMINE RECEPTOR STIMULATING AGENT; GPI 1485; LAZABEMIDE; LEVODOPA; MINOCYCLINE; NEUROPROTECTIVE AGENT; RASAGILINE; RILUZOLE; SELEGILINE; TCH 346; UBIDECARENONE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DISEASE COURSE; HUMAN; MEDICAL EXPERT; MEDICAL INFORMATION; NEUROPROTECTION; PARKINSON DISEASE; QUESTIONNAIRE;

ANIMALS; ANTIPARKINSON AGENTS; BIOLOGICAL MARKERS; CONSENSUS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PRACTICE GUIDELINES AS TOPIC; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 63449083914     PISSN: 02134853     EISSN: 15781968     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Lang AE, Lozano AJ. Parkinson's disease (part 1). N Eng J Med 1998;339: 1044-53.
2. Shapira AH, Olanow CW. Neuroproteetion in Parkinson's disease: mysteries, myths and miseoneeptions. JAMA 2004;291:2248-56.
3. Shapira AHV. Disease modifieation in Parkinson's disease. Laneet Neurol 2004;3:362-8.
4. Levy G. The relationship of Parkinson disease with aging. Areh Neurol 2007;64:1242-6.
5. Linazasoro G. Cell therapy for Parkinson's disease: only young patients allowed? Cell Transplant 2006;15:463-73.
6. De la Fuente-Fernández R. Impaet of neuroproteetion on ineidenee of Alzheimer's disease. PLoS ONE: e52. doi:10.1371/journal.pone.0000052.
7. Riedel O, Klotsehe J, Spottke A, Deusehl G, Förstl H, Henn F. Cognitive impairment in 873 patients with idiopathie Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD). J Neurol 2008;255:255-64.
8. Dik M, Deeg DJ, Visser M, Jonker C. Early life physieal aetivity and eognition at old age. J Clin Exp Neuropsyehol 2003;25:643-53.
9. Chan CS, Guzman JN, Ilijie E, Mereer JN, Riek C, Tkateh T, et al. «Rejuve- nation» proteets neurons in mouse models of Parkinson's disease. Nature 2007;447:1081-6.
10. Beeker C, Jiek SS, Meier CR. Use of antihypertensives and the risk of Parkinson's disease. Neurology 2008;70:1438-44.
11. Kempster PA, Williams DR, Selikhova M, Holton J, Revesz T, Lees AJ. Patterns of levodopa response in Parkinson's disease: a elinieo-pathologieal study. Brain 2007;130:2123-8.
12. Mattson MP, Magnus T. Ageing and neuronal vulnerability. Nat Rev Neurosei 2006;4:278-94.
13. Report of the Quality Standard Subeommittee of the Ameriean Aeademy of Neurology. Praetiee parameter: diagnosis and prognosis of new onset Parkinson's disease (an evidenee based review). Neurology 2006;66:968-75.
14. Dauer W, Przedborski S. Parkinson's disease: meehanisms and models. Neuron 2003;39:889-909.
15. Bezard E. A eall for elinieally driven experimental design in assessing neuroproteetion in experimental Parkinsonism. Behav Pharmaeol 2006;17: 379-82.
16. Beal MF. Experimental models of Parkinson's disease. Nat Rev Neurosei 2001;2:325-34.
17. Anderson DW, Bradbury KA, Sehneider JS. Neuroproteetion in Parkinson models varies with toxin administration protoeol. Eur J Neurosei 2006; 24:3174-82.
18. Seheller D, Chan P, Li Q, Wu T, Zhang R, Guan L, et al. Rotigotine treatment partially proteets from MPTP toxieity in a progressive maeaque model of Parkinson's disease. Exp Neurol 2007;2:415-22.
19. Anglade P, Vyas S, Javoy-agid F, Herrero MT, Miehel PP, Márquez J, et al. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol 1997;12:25-31.
20. Martinez-Vieente M, Cuervo AM. Autophagy and neurodegeneration: when the eleaning erew goes on strike. Laneet Neurol 2007;6:352-61.
21. Braak H, Del Trediei K, Rub U, de Vos RA, Jansen EN, Braak E. Staging of brain pathology related to sporadie PD. Neurobiol Aging 2003;24:197-211.
22. Linazasoro G. Parkinson eomplex vs elinieally signifieant Parkinson's disease. Eur J Neurol 2007;14:721-8.
23. Lang AE. The progression of Parkinson's disease. A hypothesis. Neurology 2007:68:948-52.
24. Halliday G, Hely M, Reid W, Morris J. The progression of pathology in longitudinally followed patients with Parkinson's disease. Aeta Neuropathol 2008;115:409-15.
25. Meyer-Luehmann M, Spires-Jones TL, Prada C, Gareía-Alloza M, de Calignon A, Rozkalne A, et al. Rapid appearanee and loeal toxieity of amyloid-b plaques in a mouse model of Alzheimer's disease. Nature 2008;451:720-4.
26. Kordower JH, Chu Y, Hauser RA, Freeman TB, C WOlanow CW. Lewy body-like pathology in long-term embryonie nigral transplants in Parkinson's disease. Nat Med published online, doi:10.1038/nm1747 (6 April 2008).
27. Li, J.-Y. Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, et al. Lewy bodies in grafted neurons in subjeets with Parkinson's disease suggest host-tograft disease propagation. Nat Med published online, doi:10.1038/nm1746 (6 April 2008).
28. Langston JW. The Parkinson's Complex: parkinsonism is just the tip of the ieeberg. Ann Neurol 2006;59:591-6.
29. Gasser T. Geneties of Parkinson's disease. Curr Opin Neurol 2005;18: 363-9.
30. Tolosa E, Compta Y, Gaig C. The premotor phase of Parkinson's disease. Parkinsonism Relat Disord 2007;13S:S2-7.
31. Jellinger KA. Lewy body-related alpha-synueleinopathy in the aged human brain. J Neural Transm 2004;111:1219-35.
32. 99mTe)-TRODAT-1 SPECT study. Mov Disord 2007;22:863-7.
33. Shapira AH, Obeso JA. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann Neurol 2006;59:559-62.
34. Linazasoro G. Inieio de la terapia dopaminérgiea en la enfermedad de Parkinson: seis razones para no retrasarla. Neurologia 2008;23:299-305.
35. Maswood N, Young J, Tilmont E, Zhang Z, Gash DM, Gerhardt GA, et al. Calorie restrietion inereases neurotrophie faetor levels and attenuates neuroehemieal and behavioral defieits in a primate model of Parkinson's disease. Proe Natl Aead Sei USA 2004;101:18171-6.
36. Linazasoro G. Neuroproteetion and neuroreseue in Parkinson's disease: love story or mission impossible? Exp Rev Neurotherapeuties 2002;2: 403-16.
37. Kieburtz K. Issues in neuroproteetion elinieal trials in Parkinson's disease. Neurology 2006;66:S50-7.
38. Hely MA, Morris JG, Reid WG, Traffieante R. Sydney Multieenter Study of Parkinson's disease: non-Ldopa responsive problems dominate at 15 years. Mov Disord 2005;20:190-9.
39. Hely MA, Reid WGJ, Adena MA, Halliday GM, Morris JGL. The Sydney Multieenter Study of Parkinson's Disease: the inevitability of dementia at 20 years. Mov Disord 2008;23:837-44.
40. Kraek P, Batir A, Van Blereom N, Chabardes S, Fraix V, Ardouin C, et al. Five year follow-up of bilateral stimulation of the subthalamie nueleus in advaneed Parkinson's disease. N Engl J Med 2003;349:1925-34.
41. Lueking CB, Durr A, Bonifati V, Vaughan J, De Miehele G, Gasser T, et al. Assoeiation between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med 2000;342:1560-7.
42. Parkinson Study Group. Mortality in DATATOP: a multieenter trial in early Parkinson's disease. Ann Neurol 1998;43:318-25.
43. Marras C, MeDermott, Roehon PA, Tanner CM, Naglie G, Rudolph A, et al., and the Parkinson Study Group. Survival in Parkinson disease Thirteen year follow-up of the DATATOP eohort. Neurology 2005;64:87-9.
44. Shaywitz BA, Ferrer E, Shaywitz Se. A ease of less than meets the eye. Ann Neurol 2007;62:109-11.
45. Suehowersky O, Gronseth G, Perlmutter J, Reieh S, Zesiewiez T, Weiner WJ. Praetiee parameter: neuroproteetive strategies and alternative therapies for Parkinson's disease (an evidenee-based review): report of the Quality Standards Subeommittee of the Ameriean Aeademy of Neurology. Neurology 2006;66:976-82.
46. Ravina BM, Fagan SC, Hart RG, Hovinga CA, Murphy DD, Dawson TM, et al. Neuroproteetive agents for elinieal trials in Parkinson's disease: a systematie assessment. Neurology 2003;60:1234-40.
47. Tilley BC, Paleseh YY, Kieburtz K, Ravina B, Huang P, Elm JJ, et al. Optimizing the ongoing seareh for new treatments for Parkinson disease: using futility designs. Neurology 2006;66:628-33.
48. The NINDS NET-PD Investigators. A randomized elinieal trial of eoenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 2007;68:20-8.
49. NINDS NET-PD Investigators. A randomized, double-blind, futility clinieal trial of ereatine and minoeyeline in early Parkinson disease. Neurology 2006;66:664-71.
50. Biglan KM, Holloway RG. Surrogate endpoints in Parkinson's disease re- seareh. Curr Neurol Neurosei Rep 2003;3:314-20.
51. Parkinson Study Group. Pramipexole vs levodopa as initial therapy for Parkinson's disease. JAMA 2000;284:1931-8.
52. Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, et al. In vivo imaging of mieroglial aetivation with (11C)(R)-PK11195 PET in idiopathie Parkinson's disease. Neurobiol Dis 2006;21:404-12.
53. Cicchetti F, Brownell AL, Williams K, Chen YI, Livni E, Isacson O. Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci 2002;15:991-8.
54. Schweitzer KJ, Hilker R, Walter U, Burghaus L, Berg D. Substantia nigra hyperechogenicity as a marker of predisposition and slower progression in Parkinson's disease. Mov Disord 2006;21:94-8.
55. Hauser RA, Zesiewicz TA. Clinical trials aimed at detecting neuroprotection in Parkinson's disease. Neurology 2006;66:S58-68.
56. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002;59:1937-43.
57. Youdim MD, Gross A, Finberg JP. Rasagiline [N-propargyl-1R(+)- aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 2001;132:500-6.
58. Fahn S, Oakes D, Shoulson I, and PSG group. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-508.
59. Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med 2007;5:20.
60. Lipton SA. Pathologically activated therapeutics for neuroprotection. Nature Rev Neurosci 2007;8:803-8.
61. Archer HA, Edison P, Brooks DJ. Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Ann Neurol 2006;60:145-7.
62. Eckert T, Tang C, Eidelberg D. Assessment of the progression of Painson's disease: a metabolic network approach. Lancet Neurol 2007;6:926-32.
63. Bognadov D, Matson WR, Wang L, Matson T, Saunders-Pullman R, Bressman SS, et al. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 2008;131:389-96.